Sio Gene Therapies Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q4 2014 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Sio Gene Therapies Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q4 2014 to Q4 2022.
  • Sio Gene Therapies Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2022 was -$4.02M, a 84.2% increase year-over-year.
  • Sio Gene Therapies Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2022 was -$28.8M, a 53.4% increase year-over-year.
  • Sio Gene Therapies Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$71.9M, a 122% decline from 2020.
  • Sio Gene Therapies Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$32.4M, a 55.4% increase from 2019.
  • Sio Gene Therapies Inc. annual Net Income (Loss) Attributable to Parent for 2019 was -$72.6M, a 43.7% increase from 2018.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 -$28.8M -$4.02M +$21.4M +84.2% Oct 1, 2022 Dec 31, 2022 10-Q 2023-02-14
Q3 2022 -$50.3M -$3.08M +$18.2M +85.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-02-14
Q2 2022 -$68.4M -$8.41M +$3.46M +29.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-02-14
Q1 2022 -$71.9M -$13.3M -$9.99M -300% Jan 1, 2022 Mar 31, 2022 10-K 2022-06-14
Q4 2021 -$61.9M -$25.5M -$14.9M -142% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 -$47M -$21.2M -$11.3M -113% Jul 1, 2021 Sep 30, 2021 10-Q 2023-02-14
Q2 2021 -$35.7M -$11.9M -$3.28M -38.1% Apr 1, 2021 Jun 30, 2021 10-Q 2023-02-14
Q1 2021 -$32.4M -$3.33M +$13.3M +80% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-14
Q4 2020 -$45.7M -$10.5M +$3.52M +25.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-06-14
Q3 2020 -$49.3M -$9.98M +$3.9M +28.1% Jul 1, 2020 Sep 30, 2020 10-K 2022-06-14
Q2 2020 -$53.2M -$8.59M +$19.5M +69.4% Apr 1, 2020 Jun 30, 2020 10-K 2022-06-14
Q1 2020 -$72.6M -$16.6M -$7.6M -84% Jan 1, 2020 Mar 31, 2020 10-K 2021-06-09
Q4 2019 -$65M -$14M +$20.3M +59.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-06-09
Q3 2019 -$85.3M -$13.9M +$20M +59% Jul 1, 2019 Sep 30, 2019 10-K 2021-06-09
Q2 2019 -$105M -$28.1M +$23.8M +45.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-06-09
Q1 2019 -$129M -$9.05M +$16.3M +64.3% Jan 1, 2019 Mar 31, 2019 10-K 2020-06-10
Q4 2018 -$145M -$34.3M +$23.6M +40.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-06-10
Q3 2018 -$169M -$33.8M +$35.3M +51% Jul 1, 2018 Sep 30, 2018 10-K 2020-06-10
Q2 2018 -$204M -$51.9M +$17.4M +25.1% Apr 1, 2018 Jun 30, 2018 10-K 2020-06-10
Q1 2018 -$222M -$25.3M +$27.5M +52.1% Jan 1, 2018 Mar 31, 2018 10-K 2019-06-11
Q4 2017 -$249M -$57.9M -$10.1M -21.1% Oct 1, 2017 Dec 31, 2017 10-K 2019-06-11
Q3 2017 -$239M -$69.1M -$26.8M -63.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-06-11
Q2 2017 -$212M -$69.3M -$31.2M -82% Apr 1, 2017 Jun 30, 2017 10-K 2019-06-11
Q1 2017 -$181M -$52.8M -$23.2M -78.1% Jan 1, 2017 Mar 31, 2017 10-K 2018-06-11
Q4 2016 -$158M -$47.8M +$15.5M +24.5% Oct 1, 2016 Dec 31, 2016 10-K 2018-06-11
Q3 2016 -$173M -$42.3M -$27.1M -179% Jul 1, 2016 Sep 30, 2016 10-K 2018-06-11
Q2 2016 -$146M -$38.1M -$13.1M -52.5% Apr 1, 2016 Jun 30, 2016 10-K 2018-06-11
Q1 2016 -$133M -$29.7M -$19.4M -188% Jan 1, 2016 Mar 31, 2016 10-K 2017-06-13
Q4 2015 -$114M -$63.4M -$52.6M -489% Oct 1, 2015 Dec 31, 2015 10-K 2017-06-13
Q3 2015 -$61.2M -$15.2M Jul 1, 2015 Sep 30, 2015 10-K 2017-06-13
Q2 2015 -$25M Apr 1, 2015 Jun 30, 2015 10-K 2017-06-13
Q1 2015 -$10.3M Jan 1, 2015 Mar 31, 2015 10-K 2016-06-06
Q4 2014 -$10.8M Nov 1, 2014 Dec 31, 2014 10-K 2016-06-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.